ASXL1 and acute myeloid leukemia: The HDAC inhibitor vorinostat reverses histone acetylation at these promoter regions and induces transcriptional derepression of the TGF-β pathway genes with a simultaneous growth-inhibition effect in ASXL1 mutants, indicating that HDAC inhibitors will be promising therapeutic drugs for MDS and AML with ASXL1 and SETBP1 mutations (224).